Venalot Depot 180mg 30mg, 30 Pills, Troxerutin, Coumarin
INDICATIONS: Treatment of varicose syndrome: phlebitis, thrombosis, thrombophlebitis, lymphatic congestion, lymphangitis, hemorrhoids, postoperative and posttraumatic edema.
Pharmacokinetics HUMAN Venalot Depot ® contains active substances coumarin and troxerutin; these substances belonging to the families of the benzopyrones. Coumarin is a 5,6-benzo-alpha-pyrone and troxerutin is a semi-synthetic derivative of rutoside with the basic structure of a 2-phenylbenzo-gamma-pyrone.
5,6-benzo-alpha-pyrone not be regarded as a vitamin K antagonist (4-hydroxycoumarin), because it lacks the 4-hydroxy group and, therefore, has no anticoagulant effect.
Human studies demonstrate that coumarin, after oral administration, is rapidly absorbed. The substance in the systemic circulation is unchanged at 4% as metabolites by 96%. The plasma elimination of coumarin biotransformation is performed by 7-hydroxy-coumarin, which is conjugated to 7-hydroxycoumarin-glucuronide, which is excreted renally 90%. Between 20 and 100 ng / ml are considered as a therapeutic plasma level for coumarin.
Following absorption, coumarin binds to albumin and other plasma proteins. After administration of the optimal dose, a large proportion of the interstitial plasma proteins reach the maximum carrying amount of coumarin attached to these proteins. This complex-albumin coumarin is phagocytosed by macrophages and monocytes, resulting in amino acids and peptides which are simultaneously released into the extracellular proteases. The protein fragments of the addition product of these processes are removed from the gap through the veins, in contrast to the proteins of high molecular weight which depend on the lymphatic system to be removed. Therefore, these protein fragments of lower molecular weight, high diffusion coefficient and its consequent ability to penetrate small pores play a role in the mechanism of action of Venalot Depot ®. After the removal of proteins accumulated fluid drainage is performed accordingly and tissue restoration. The immediate effect of coumarin rheological and troxerutin is based on increasing the plasticity of the erythrocytes.
Troxerutin absorbed between 10 and 15% after oral administration and is bound to plasma proteins in 30%. It is excreted in a higher proportion in bile and to a lesser extent in the urine.
After oral administration of 500 mg / kg in solution, more than 6% of troxerutin and its metabolites are excreted via the kidney during the first 40 hours, with an increased excretion rate constant. It has a half-life of 18.3 hours.
The plasma concentration of troxerutin and its metabolites (dihydroxytoluene and hydroxy phenyl acetic acid) begins to increase from 4 to 8 hours after administration, reaching the maximum level of 8 to 12 hours. The elimination half-life begins between 3.2 and 14.4 hours.
In the urine of 48 hours is 50.5% of the metabolites of troxerutin the dose employed. The therapeutic plasma level is from 45 to 255 pmol / ml.
Pharmacological Action: Venalot DEPOT ® has the following: anti-inflammatory, linfocinética, endotelioprotectora, increases macrophage phagocytic capacity and increases the plasticity of the erythrocytes.
By its action multiple Venalot DEPOT ® is a resource in the treatment of peripheral vascular diseases, whether they are of type venous, arterial or lymphatic. Venalot DEPOT ® is useful in high-protein edema, as often occurs in the venous and lymphatic congestion.
CONTRAINDICATIONS: Do not administer to patients with liver disease or a history of liver disease, hypersensitivity to the components of the formula.
RESTRICTIONS OF USE DURING PREGNANCY AND LACTATION: The use of this drug during pregnancy and lactation is under the responsibility of the physician.
ADVERSE REACTIONS: Hyperacidity, flushing, headache. The patient should discontinue treatment and inform your doctor if you experience the following symptoms: nausea accompanied by urticaria, dark-colored urine or yellowing of the skin and / or eyeball.
There have been isolated reports of hepatitis with or without jaundice, which were reversible after discontinuation.
There have been isolated reports of gastrointestinal upset.
DRUG INTERACTIONS AND OTHER GENDER: Coadministration with drugs that alter liver function, may increase the likelihood of hepatic reactions. Venalot DEPOT ® can be given concomitantly in patients taking anticoagulants.
CHANGES IN RESULTS OF LABORATORY TESTS: Occasionally there may be increased liver enzymes (transaminases and serum gamaglutamil transpeptidase), predominantly during the initial phase of treatment, these increases are normalized when treatment is stopped.
Depot ® Venalot not alter blood clotting, so that such periodic tests are not necessary.
PRECAUTIONS IN RELATION TO EFFECTS Carcinogenesis, Mutagenesis, Impairment of Fertility: So far not submitted any of these effects.
DOSAGE AND ADMINISTRATION: Oral.
In venous diseases, postoperative edema, impaired wound healing and lymphedema: One tablet every 12 hours.
In severe cases, a tablet every 8 hours.
MANIFESTATIONS AND MANAGEMENT OF OVERDOSE OR ACCIDENTAL INGESTION: So far, no known overdose poisoning.
PRESENTATION: Box of 30 tablets.
RECOMMENDED STORAGE: Store at room temperature not exceeding 30 ° C and dry.
Drug Name: Venalot Depot
Comparative Brand: Venalot Depot
Active ingredient: Troxerutin / Coumarin
Response time: No
Laboratory: Nycomed, S. A. de CV
Box with 30 pills
Manufactured in: Mexico